Ascletis expects to submit an Investigational New Drug Application (IND) for ASC36 for the treatment of obesity to the US Food and Drug Administration (FDA) in the second quarter of 2026. ASC36, an ...
SHELTON, CONNECTICUT / ACCESS Newswire / October 29, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), announced that Nanoviricides CEO Dr Anil Diwan joined ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback